SouthState Corp’s Definium Therapeutics DFTX Stock Holding History

SouthState Corp’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-352	Closed	-$7K	–	751
2021 Q4	$7K	Buy	+352	New	+$11.2K	﹤0.01%	607

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

SouthState Corp's DFTX Position: Q1 2022 in Review

SouthState Corp sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 352 shares — an estimated $7K sold.

SouthState Corp first reported a position in DFTX in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

SouthState Corp reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
SouthState Corp sold 352 Definium Therapeutics shares in Q1 2022, an estimated $7K.
SouthState Corp first reported a position in Definium Therapeutics in Q4 2021 and held it in 1 quarter.
SouthState Corp's Definium Therapeutics position peaked at $7K in Q4 2021.
159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on SouthState Corp's 13F filing for Q1 2022, filed 6 May 2022.